Millie
your market intelligence analyst
Search Results
526 results
Your search is now limited to «Drugs» expert search.
Healio News 10/22/2019 11:49
Guidelines fall short in diagnosing labile hypertension, addressing adherence.
More from Healio News:
Cardiac Rhythm News 10/22/2019 11:19
The US Food and Drug Administration (FDA) has approved Farxiga (dapaglifozin, AstraZeneca) to reduce the risk of hospitalisation for heart failure in adults with type 2 diabetes and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors.
More from Cardiac Rhythm News:
News-Medical.net 10/22/2019 08:15
Obesity itself is considered a major risk factor for cardiovascular disease, and a major risk as well for diabetes and high blood pressure, which are other top cardiovascular risks.
More from News-Medical.net:
PR Newswire 10/22/2019 07:00
These changes lead to high arterial pressure, right heart strain, and ultimately, right heart failure and death.
More from PR Newswire:
PMLiVE 10/22/2019 04:26
This is promising news for the 30 million people living with type 2 diabetes in the US, as heart failure is one of the earliest cardiovascular complications for them, before heart attack or stroke,” said Ruud Dobber, executive vice president of biopharmaceuticals at AZ.
More from PMLiVE:
FeedNavigator (EU) 10/22/2019 04:07
Nondiabetic hypertensive patients have a high prevalence of prediabetes [6], and the incidence of T2D in the general population is high as baseline blood pressure values are generally elevated [7.
More from FeedNavigator (EU):
AstraZeneca has secured approval from the US Food and Drug Administration (FDA) for its Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure (hHF) in adults with type-2 diabetes (T2D) and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors.
More from Pharmaceutical Business Review:
Medical Research News 10/21/2019 18:55
The results from the OPTIMA analysis suggest that initial treatment with macitentan in combination with tadalafil is associated with hemodynamic improvement in newly diagnosed patients with pulmonary arterial hypertension.
More from Medical Research News:
ENDPOINTS 10/21/2019 08:55
The results showed that the Farxiga treatment did trigger a lower rate of hospitalization for heart failure — but the therapy was not better or worse than placebo in its impact on the rate of major adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction, or ischemic stroke.
More from ENDPOINTS:
ClinicalTrials.gov 10/21/2019 08:11
Condition : Paroxysmal Atrial Fibrillation Intervention : Device: POLARx™ Cardiac Cryoablation System Sponsor : Boston Scientific Corporation Not yet recruiting.
More from ClinicalTrials.gov:
Business Wire 10/21/2019 07:00
This is promising news for the 30 million people living with type 2 diabetes in the US, as heart failure is one of the earliest cardiovascular complications for them, before heart attack or stroke.
More from Business Wire:
ETHealthWorld (India) 10/21/2019 03:07
The approval by the U.S. Food and Drug Administration is based on results from the DECLARE-TIMI 58 clinical trial, the British drugmaker said and follows a similar approval by the European authorities in August.
More from ETHealthWorld (India):
Reuters.com 10/21/2019 02:35
Diabetes is associated with a high risk of heart failure.
More from Reuters.com:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications